programas cribado cancer


Nota Bibliográfica

Esta Nota es una recopilación de publicaciones (artículos, informes, libros) sobre cribado de cáncer resultado de una revisión no sistemática de la literatura.

Podéis dirigir vuestros comentarios o sugerencias sobre la Nota a:

Josep A Espinás. Pla Director d'Oncología de Catalunya.
Correo electrónico: Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla


Lunes, 08 de Enero de 2018 13:34


Ir a documento




Ir a documento


Nota bibliográfica cribado c próstata 2014-11

Kitagawa Y, Sawada K, Urata S, Izumi K, Ueno S, Kadono Y, et al. Impact of PSA Levels on Second-round Screening for the Development of Prostate Cancer in Men with Low Baseline PSA Levels (Anticancer Res. Greece; 2014;34(11):6739–46. PMID: 25368284.

CONCLUSION: The present study demonstrated that serum PSA levels at second round screening were a strong predictor of cancer development in men with baseline PSA levels ng/ml at the first population screening.

Prasad V. It is time to stop screening for prostate cancer. JAMA Intern Med. United States; 2014;174(11):1841–2. doi: 10.1001/jamainternmed.2014.3078.
PMID: 25178980.

Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2014; Available from: doi: 10.1093/annonc/mdu525.

Conclusions Risk prediction models improve the predictive accuracy of PSA testing to detect PCa. Future developments in the use of PCa risk models should evaluate its clinical effectiveness in practice


Nota bibliográfica cribado c próstata 2014-10

Ghodsbin F, Zare M, Jahanbin I, Ariafar A, Keshavarzi S. A Survey of the Knowledge and Beliefs of Retired Men about Prostate Cancer Screening Based on Health Belief Model. Int J community based Nurs midwifery. Iran; 2014;2(4):279–85. PMID: 25349871.

CONCLUSION: Developing an assessment based on HBM could be effective in designing and implementing educational programs by helping to identify the needs and priorities of the target population.

Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, et al. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol. 2014; doi: 10.1007/s00345-014-1426-y. PMID: 25358675.

CONCLUSION: No significant differences in PSA levels or PCa incidence and grade were observed. The slightly higher f/t-ratio did not result in lower PCa detection rate. Metformin users were at significantly higher risk of all-cause mortality. The relatively small number of men on metformin is a main limitation of the study.

Black A. A targeted approach reduces prostate cancer-specific (PSA) screening harms while preserving benefits. Evid Based Med. England; 2014;19(5):186. doi: 10.1136/ebmed-2014-110018. PMID: 24939923


Nota bibliográfica cribado c próstata 2014-07/08

Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, et al. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer. 2014;135(4):939–47. Available from:  doi: 10.1002/ijc.28732. PMID: 24443367.
Prostate-specific antigen (PSA) screening for prostate cancer may reduce mortality, but it incurs considerable risk of over diagnosis and potential harm to quality of life. Our objective was to evaluate the cost-effectiveness of PSA screening, with and without adjustment for quality of life, for the British Columbia (BC) population. We adapted an existing natural history model using BC incidence, treatment, cost and mortality patterns. The modeled mortality benefit of screening derives from a stage-shift mechanism, assuming mortality reduction consistent with the European Study of Randomized Screening for Prostate Cancer. The model projected outcomes for 40-year-old men under 14 combinations of screening ages and frequencies. Cost and utility estimates were explored with deterministic sensitivity analysis. The incremental cost-effectiveness of regular screening ranged from $36,300/LYG, for screening every four years from ages 55 to 69 years, to $588,300/LYG, for screening every two years from ages 40 to 74 years. The marginal benefits of increasing screening frequency to 2 years or starting screening at age 40 years were small and came at significant cost. After utility adjustment, all screening strategies resulted in a loss of quality-adjusted life years (QALYs); however, this result was very sensitive to utility estimates. Plausible outcomes under a range of screening strategies inform discussion of prostate cancer screening policy in BC and similar jurisdictions. Screening may be cost-effective, but the sensitivity of results to utility values suggests individual preferences for quality versus quantity of life should be a key consideration.


Página 1 de 14

web desarrollada y mantenida por :